Merck & Co., Inc. and Veracyte, Inc.: SG&A Spending Patterns Compared

SG&A Spending Patterns: A Tale of Two Companies

In the ever-evolving landscape of the pharmaceutical and biotechnology sectors, understanding spending patterns is crucial. Merck & Co., Inc., a titan in the pharmaceutical industry, and Veracyte, Inc., a rising star in genomic diagnostics, present a fascinating study in contrasts. Over the past decade, Merck's Selling, General, and Administrative (SG&A) expenses have shown a steady pattern, peaking in 2014 and 2019, with a slight dip in 2020. In contrast, Veracyte's SG&A expenses have surged, growing by over 350% from 2014 to 2023. This growth reflects Veracyte's aggressive expansion and investment in innovation. While Merck's SG&A expenses are approximately 100 times larger than Veracyte's, the latter's rapid growth trajectory highlights its potential to disrupt the market. This comparison underscores the diverse strategies companies employ to navigate the competitive landscape.